Panitumumab is a recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR).
- Mechanism
- Curator reviewed
Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.
- Primary indication
- For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.Curator reviewed · 3 structured indications
- First approval
- Canada, 2008 · United States, 2006 · European Union, 2016
- Code names
- E7.6.3 · QL1203
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Panitumumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account